Why take this course?
Artificial intelligence is increasingly influencing GMP decisions across deviation investigations, batch review, predictive maintenance, quality risk assessment, CAPA effectiveness, and manufacturing support. These systems can identify patterns and process large datasets quickly, but their recommendations may be inaccurate, biased, difficult to explain, or inconsistent with experienced human judgment. At the same time, human decisions can also be affected by cognitive bias, incomplete analysis, and inconsistent reasoning.
This webinar examines how regulated organizations can manage disagreements between AI recommendations and human judgment without weakening accountability. Participants will consider decision authority, mandatory human review, escalation pathways, documentation practices, and governance controls for AI-assisted decisions. The focus is on determining when recommendations should be accepted, questioned, or overridden, while preserving regulatory responsibility, product quality, patient safety, and inspection readiness within FDA-regulated GMP operations as AI becomes more embedded in routine quality and manufacturing decisions.
Key Areas Covered
Commonly Asked Questions About This Subject
When a qualified employee overrides an AI recommendation, what evidence makes that decision defensible months later?
The strongest record explains what the employee knew at the time, why the AI recommendation was considered insufficient, and what evidence supported the alternative decision. A statement such as "SME judgment applied" provides very little protection during a later investigation or inspection.
This becomes particularly important when the outcome is unfavorable. Reviewers may reconstruct the decision using information that was unavailable when it was originally made. Without a contemporaneous rationale, a reasonable judgment can appear arbitrary after the event.
Useful documentation identifies the conflicting recommendation, relevant source data, assumptions or limitations identified in the AI output, additional evidence considered, and the reasoning that led to the final disposition. The depth should reflect the potential GMP consequence of the decision.
A defensible override shows that disagreement with the system resulted from deliberate evaluation rather than preference, intuition, or resistance to an inconvenient recommendation.
What should happen when employees repeatedly reject recommendations from the same AI system?
Repeated disagreement should trigger evaluation of the system and its intended use rather than being treated indefinitely as a series of unrelated decisions. A pattern of overrides can provide valuable evidence that the system is performing differently from what was expected or is being applied under conditions that were poorly represented during qualification.
The pattern itself matters. Are overrides concentrated around one product, process condition, decision type, data source, or user group? Do experienced personnel consistently identify the same weakness? Are recommendations technically correct but operationally unusable?
Inspection friction develops when records show frequent rejection of AI outputs while periodic reviews continue concluding that the system performs acceptably without addressing the discrepancy.
Override data should therefore become an operational performance signal. Trending the reasons for disagreement can expose inappropriate intended-use boundaries, poor input data, changing process conditions, or weaknesses in the system's decision logic before those weaknesses contribute to a significant quality event.
How should a GMP team handle a situation where the AI recommendation appears better supported by the data than the employee's judgment?
Seniority or experience alone should not automatically settle the disagreement. If the available evidence supports the AI recommendation more strongly, the employee's alternative conclusion should withstand the same scrutiny that would be applied to any other consequential GMP decision.
This situation can be uncomfortable because organizations sometimes design escalation processes around the assumption that humans will identify AI errors. The reverse can also occur. An experienced decision-maker may rely on historical practice, incomplete information, or a familiar interpretation that current data no longer supports.
The appropriate response is structured examination of the disagreement, including the underlying data, assumptions, decision criteria, system limitations, and employee rationale. Higher-risk disagreements may require independent technical or quality review.
What becomes difficult to defend is a record showing that a well-supported recommendation was rejected simply because an authorized individual preferred another conclusion. Decision authority does not remove the obligation to justify the decision scientifically.
What becomes the biggest inspection vulnerability when AI-assisted decisions produce acceptable outcomes for months without being challenged?
Successful outcomes can create false confidence in the decision process. If recommendations are routinely accepted because previous recommendations appeared reasonable, reviewers may eventually question whether meaningful evaluation is still occurring.
This weakness can remain hidden because there may be no deviations, rejected batches, complaints, or obvious failures to expose it. Records show approvals, the process continues operating, and the system appears effective. Over time, however, users may stop examining assumptions, source data, unusual outputs, or subtle changes in recommendation patterns.
Evidence of controlled use should therefore include more than records showing that decisions were approved. Periodic examination of accepted recommendations, unusual cases, near misses, override patterns, and subsequent outcomes can demonstrate that continued reliance remains justified.
During an inspection, a long history of successful AI-assisted decisions is useful evidence only when the organization can also show that those decisions continued receiving meaningful scrutiny rather than becoming routine acceptance.
Your TalkFDA Webinar Experience
1. Confirmation
3. Join the Live Training
4. Watch Again Anytime
Testimonials
Ready to Strengthen Your Team? Let’s Build Your Training Plan.
Your team deserves the clarity.
Your organization deserves the confidence.


